TRATAMIENTO DE LA GOTA AGUDA

Gout has been amply described from the times of Galen and it continues to be a public health problem that causes important morbidity in the world population. The treatment of acute gout has not changed in the last years, but a current review and actualization of the medical literature is necessary since there are continuous flaws in the management of this illness, not only in the actual indication of specific drugs, but also in the attentive care required due to the potential development of side effects from the traditional medications used in the treatment.

[1]  J. Levin,et al.  Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.

[2]  R. Wortmann.  Recent advances in the management of gout and hyperuricemia , 2005, Current opinion in rheumatology.

[3]  T. Mikuls,et al.  Understanding treatments for gout. , 2005, The American journal of managed care.

[4]  Hyon K. Choi.  Diet, alcohol, and gout: How do we advise patients given recent developments? , 2005, Current rheumatology reports.

[5]  Hyon K. Choi,et al.  Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. , 2005, Arthritis and rheumatism.

[6]  G. Nuki.  Treatment of crystal arthropathy--history and advances. , 2006, Rheumatic diseases clinics of North America.

[7]  Hyon K. Choi,et al.  Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. , 2007, Arthritis and rheumatism.

[8]  C. Siva,et al.  Diagnosing acute monoarthritis in adults: a practical approach for the family physician. , 2003, American family physician.

[9]  H. Schumacher,et al.  Newer therapeutic approaches: gout. , 2006, Rheumatic diseases clinics of North America.

[10]  J. MacKenzie,et al.  Imaging features of crystal-induced arthropathy. , 2006, Rheumatic diseases clinics of North America.

[11]  F. Lioté,et al.  Gout: update on some pathogenic and clinical aspects. , 2006, Rheumatic diseases clinics of North America.

[12]  R. Flores,et al.  Acute monarthritis: diagnosis and management. , 2006, Primary care.

[13]  G. Varughese,et al.  Colchicine in acute gout , 2003, BMJ : British Medical Journal.

[14]  A. Eggebeen.  Gout: an update. , 2007, American family physician.

[15]  Hyon K. Choi,et al.  Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease , 2007, Circulation.

[16]  S. Navarra,et al.  Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. , 2004, Arthritis and rheumatism.

[17]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[18]  W. Bilker,et al.  Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 , 2005, Annals of the rheumatic diseases.

[19]  R. Wortmann,et al.  Management of Gout in Older Adults , 2007, Drugs & aging.

[20]  Hyon K. Choi,et al.  Pathogenesis of Gout , 2005, Annals of Internal Medicine.

[21]  Chaoyang Li,et al.  Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. , 2007, Arthritis and rheumatism.

[22]  P. Routledge,et al.  Colchicine induced rhabdomyolysis , 2001, Postgraduate medical journal.

[23]  Hyon K. Choi,et al.  AMERICAN COLLEGE OF PHYSICIANS; AMERICAN PHYSIOLOGICAL SOCIETY. PATHOGENESIS OF GOUT , 2005 .

[24]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[25]  G. Starkebaum,et al.  Colchicine induced rhabdomyolysis. , 1997, The Journal of rheumatology.

[26]  T. Cheng,et al.  A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. , 2004, Clinical therapeutics.

[27]  C. Weinberg,et al.  Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. , 1991, Annals of internal medicine.

[28]  Hyon K. Choi,et al.  Lifestyle and gout , 2008, Current opinion in rheumatology.

[29]  M. Jolly,et al.  Hyperuricemia and associated diseases. , 2006, Rheumatic diseases clinics of North America.

[30]  T. Pope,et al.  Gout: a clinical and radiologic review. , 2004, Radiologic clinics of North America.

[31]  C K Yeung,et al.  Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Bonnel,et al.  Deaths associated with inappropriate intravenous colchicine administration. , 2002, The Journal of emergency medicine.

[33]  R. Willburger,et al.  Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.

[34]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[35]  Hyon K. Choi.  Epidemiology of crystal arthropathy. , 2006, Rheumatic diseases clinics of North America.

[36]  S. Gabriel,et al.  Epidemiology of gout: is the incidence rising? , 2002, The Journal of rheumatology.

[37]  C. Wise.  Crystal-associated arthritis in the elderly. , 2000, Rheumatic diseases clinics of North America.

[38]  D. Mount,et al.  Renal urate transport. , 2006, Rheumatic diseases clinics of North America.

[39]  P. Macdonald,et al.  Clinical trials in crystal arthropathy. , 2006, Rheumatic diseases clinics of North America.

[40]  M. Doherty,et al.  The changing epidemiology of gout , 2007, Nature Clinical Practice Rheumatology.

[41]  N. Schlesinger.  Diagnosis of gout: clinical, laboratory, and radiologic findings. , 2005, The American journal of managed care.

[42]  G. Alaylı,et al.  Acute Myopathy in a Patient with Concomitant Use of Pravastatin and Colchicine , 2005, The Annals of pharmacotherapy.

[43]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[44]  S. Kong,et al.  A literature review of the epidemiology and treatment of acute gout. , 2003, Clinical therapeutics.

[45]  C. Torrance,et al.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. , 1992, The New England journal of medicine.

[46]  D. Furst,et al.  Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[47]  W. Willett,et al.  Coffee consumption and risk of incident gout in men: a prospective study. , 2007, Arthritis and rheumatism.

[48]  C. Wise.  Crystal-associated arthritis in the elderly. , 2005, Clinics in geriatric medicine.

[49]  M. Underwood.  Diagnosis and management of gout , 2006, BMJ : British Medical Journal.

[50]  R. Burgos-Vargas,et al.  Metabolic Syndrome and Ischemic Heart Disease in Gout , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[51]  A. Romanowicz,et al.  Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. , 1991, Current medical research and opinion.

[52]  M. Keith,et al.  Updates in the management of gout. , 2007, The American journal of medicine.

[53]  Hyon K. Choi,et al.  Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. , 2005, Archives of internal medicine.

[54]  H. Christian,et al.  Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. , 2002, Arthritis and rheumatism.

[55]  P. Brooks,et al.  Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.

[56]  D. Hunter,et al.  Alcohol consumption as a trigger of recurrent gout attacks. , 2006, The American journal of medicine.

[57]  J. Boice,et al.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis , 2002, BMJ : British Medical Journal.

[58]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[59]  F. Sivera,et al.  Therapeutic advances in gout , 2007, Current opinion in rheumatology.

[60]  M. A. Winblad,et al.  Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. , 1986, The American journal of medicine.